Erratum: Loss of heterozygosity analysis in malignant gliomas (Brain Tumor Pathol DOI: 10.1007/s10014-011-0038-0);Loss of heterozygosity analysis in malignant gliomas

Brain Tumor Pathology

Volumn 28, Issue 3, 2011, Pages 191-196

  Mizoguchi, Masahiro ^a   Kuga, Daisuke ^a   Guan, Yanlei ^a   Hata, Nobuhiro ^a   Nakamizo, Akira ^a   Yoshimoto, Koji ^a   Sasaki, Tomio ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

1p 19q; LOH; Malignant glioma; UPD

Indexed keywords

ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ACQUIRED UNIPARENTAL DISOMY; ALLELE; CANCER CLASSIFICATION; CHROMOSOME 10; CHROMOSOME 10P; CHROMOSOME 10Q; CHROMOSOME 19P; CHROMOSOME 1P; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; COPY NEUTRAL LOSS OF HETEROZYGOSITY; COPY NUMBER VARIATION; DNA METHYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE MUTATION; GENOME ANALYSIS; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; MITOSIS; POLYMERASE CHAIN REACTION; PROMOTER REGION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE; UNIPARENTAL DISOMY;

EID: 80052751470     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-011-0049-x     Document Type: Erratum

References (60)

1. Louis DN, Ohgaki H, Weistler OD et al (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer (IARC), Lyon
2. R McLendon A Friedman D Bigner, et al. 2008 Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 1061 1068 10.1038/nature07385 1:CAS:528:DC%2BD1cXht1yju77J
3. DW Parsons S Jones X Zhang, et al. 2008 An integrated genomic analysis of human glioblastoma multiforme Science 321 1807 1812 18772396 10.1126/science.1164382 1:CAS:528:DC%2BD1cXhtFCrtLrE
4. H Ohgaki P Kleihues 2009 Genetic alterations and signaling pathways in the evolution of gliomas Cancer Sci 100 2235 2241 19737147 10.1111/j.1349-7006. 2009.01308.x 1:CAS:528:DC%2BD1MXhsFOltrvN
5. AG Knudson Jr 1971 Mutation and cancer: statistical study of retinoblastoma Proc Natl Acad Sci USA 68 820 823 5279523 10.1073/pnas.68.4.820
6. WK Cavenee TP Dryja RA Phillips, et al. 1983 Expression of recessive alleles by chromosomal mechanisms in retinoblastoma Nature 305 779 784 6633649 10.1038/305779a0 1:STN:280:DyaL2c%2FjvFOrtA%3D%3D (Pubitemid 13010953)
7. P Devilee AM Cleton-Jansen CJ Cornelisse 2001 Ever since Knudson Trends Genet 17 569 573 11585662 10.1016/S0168-9525(01)02416-7 1:CAS:528: DC%2BD3MXnt1Wju70%3D (Pubitemid 32918298)
8. M Tuna S Knuutila GB Mills 2009 Uniparental disomy in cancer Trends Mol Med 15 120 128 19246245 10.1016/j.molmed.2009.01.005 1:CAS:528: DC%2BD1MXjt1ahu70%3D
9. ER Mardis 2011 A decade's perspective on DNA sequencing technology Nature 470 198 203 21307932 10.1038/nature09796 1:CAS:528:DC%2BC3MXhslWktbk%3D
10. K Yoshimoto T Iwaki T Inamura, et al. 2002 Multiplexed analysis of post-PCR fluorescence-labeled microsatellite alleles and statistical evaluation of their imbalance in brain tumors Jpn J Cancer Res 93 284 290 11927010 1:CAS:528:DC%2BD38XktFSlur4%3D (Pubitemid 34464364)
11. A Idbaih Y Marie G Pierron, et al. 2005 Two types of chromosome 1p losses with opposite significance in gliomas Ann Neurol 58 483 487 16130103 10.1002/ana.20607 1:CAS:528:DC%2BD2MXhtFWqsr7L (Pubitemid 41266639)
12. R Beroukhim G Getz L Nghiemphu, et al. 2007 Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma Proc Natl Acad Sci USA 104 20007 20012 18077431 10.1073/pnas.0710052104 1:CAS:528:DC%2BD1cXhs1WmtQ%3D%3D
13. N Hata 2006 Allelic losses of chromosome 10 in glioma tissues detected by quantitative single-strand conformation polymorphism analysis Clin Chem 52 370 378 16397012 10.1373/clinchem.2005.060954 1:CAS:528:DC%2BD28Xit1Sht78%3D
14. Y Guan N Hata D Kuga, et al. 2008 Narrowing of the regions of allelic losses of chromosome 1p36 in meningioma tissues by an improved SSCP analysis Int J Cancer 122 1820 1826 18092328 10.1002/ijc.23297 1:CAS:528: DC%2BD1cXksFeit70%3D (Pubitemid 351413429)
15. M Snuderl AF Eichler KL Ligon, et al. 2009 Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss Clin Cancer Res 15 6430 6437 19808867 10.1158/1078-0432.CCR-09-0867 1:CAS:528:DC%2BD1MXhtlyqsb%2FE
16. D Kuga M Mizoguchi Y Guan, et al. 2008 Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues Neuro-Oncology 10 995 1003 18697953 10.1215/15228517-2008-064 1:CAS:528:DC%2BD1MXmvV2htA%3D%3D
17. D Yin S Ogawa N Kawamata, et al. 2009 High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray Mol Cancer Res 7 665 677 19435819 10.1158/1541-7786.MCR-08-0270 1:CAS:528:DC%2BD1MXmtFCisLk%3D
18. BA Walker 2006 Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma Blood 108 1733 1743 16705090 10.1182/blood-2006-02-005496 1:CAS:528:DC%2BD28Xpt1Slurg%3D (Pubitemid 44316144)
19. EG Van Meir T Kikuchi M Tada, et al. 1994 Analysis of the p53 gene and its expression in human glioblastoma cells Cancer Res 54 649 652 8306326 (Pubitemid 24068319)
20. KC Lo D Bailey T Burkhardt, et al. 2008 Comprehensive analysis of loss of heterozygosity events in glioblastoma using the 100K SNP mapping arrays and comparison with copy number abnormalities defined by BAC array comparative genomic hybridization Genes Chromosom Cancer 47 221 237 18050302 10.1002/gcc.20524 1:CAS:528:DC%2BD1cXhsFSgtrw%3D (Pubitemid 351162853)
21. G Yamamoto Y Nannya M Kato, et al. 2007 Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays Am J Hum Genet 81 114 126 17564968 10.1086/518809 1:CAS:528:DC%2BD2sXnt1CksLg%3D (Pubitemid 47001161)
22. C Li R Beroukhim BA Weir, et al. 2008 Major copy proportion analysis of tumor samples using SNP arrays BMC Bioinforma 9 204 10.1186/1471-2105-9-204 (Pubitemid 351663943)
23. Z Liu A Li V Schulz, et al. 2010 MixHMM: inferring copy number variation and allelic imbalance using SNP arrays and tumor samples mixed with stromal cells PLoS One 5 e10909 20532221 10.1371/journal.pone.0010909
24. JG Cairncross K Ueki MC Zlatescu, et al. 1998 Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1473 1479 9776413 10.1093/jnci/90.19. 1473 1:STN:280:DyaK1cvkslejug%3D%3D (Pubitemid 28482012)
25. Y Ino RA Betensky MC Zlatescu, et al. 2001 Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis Clin Cancer Res 7 839 845 11309331 1:STN:280:DC%2BD3M3pvFGqtw%3D%3D (Pubitemid 32708719)
26. DN Louis EC Holland JG Cairncross 2001 Glioma classification: a molecular reappraisal Am J Pathol 159 779 786 11549567 10.1016/S0002-9440(10)61750-6 1:CAS:528:DC%2BD3MXnt12ms7o%3D (Pubitemid 32847166)
27. G Cairncross 2006 Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J Clin Oncol 24 2707 2714 16782910 10.1200/JCO.2005.04.3414 1:CAS:528: DC%2BD28XntV2hurg%3D (Pubitemid 46630566)
28. MJ van den Bent 2006 Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 2715 2722 16782911 10.1200/JCO.2005.04.6078 (Pubitemid 46630567)
29. RB Jenkins H Blair KV Ballman, et al. 2006 A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 9852 9861 17047046 10.1158/0008-5472.CAN- 06-1796 1:CAS:528:DC%2BD28XhtVyiur3I (Pubitemid 44672036)
30. CA Griffin P Burger L Morsberger, et al. 2006 Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss J Neuropathol Exp Neurol 65 988 994 17021403 10.1097/01.jnen.0000235122.98052.8f (Pubitemid 44521799)
31. H Ohgaki P Kleihues 2007 Genetic pathways to primary and secondary glioblastoma Am J Pathol 170 1445 1453 17456751 10.2353/ajpath.2007.070011 1:CAS:528:DC%2BD2sXlvFCns74%3D (Pubitemid 47339290)
32. M Nakamura F Yang H Fujisawa, et al. 2000 Loss of heterozygosity on chromosome 19 in secondary glioblastomas J Neuropathol Exp Neurol 59 539 543 10850866 1:CAS:528:DC%2BD3cXktlWrtbk%3D (Pubitemid 30368313)
33. JS Smith B Alderete Y Minn, et al. 1999 Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype Oncogene 18 4144 4152 10435596 10.1038/sj.onc.1202759 1:CAS:528:DyaK1MXkvFChtLk%3D (Pubitemid 29363922)
34. C Hartmann L Johnk G Kitange, et al. 2002 Transcript map of the 3.7-Mb D19S112-D19S246 candidate tumor suppressor region on the long arm of chromosome 19 Cancer Res 62 4100 4108 12124348 1:CAS:528:DC%2BD38XlsV2lsbc%3D (Pubitemid 34791081)
35. M Mizoguchi CL Nutt DN Louis 2004 Mutation analysis of CBL-C and SPRED3 on 19q in human glioblastoma Neurogenetics 5 81 82 14618415 10.1007/s10048-003- 0164-x (Pubitemid 38297480)
36. A Mukasa K Ueki S Matsumoto, et al. 2002 Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p Oncogene 21 3961 3968 12037678 10.1038/sj.onc.1205495 1:CAS:528:DC%2BD38XkslWqt7Y%3D (Pubitemid 34679237)
37. F Ducray A Idbaih A de Reynies, et al. 2008 Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile Mol Cancer 7 41 18492260 10.1186/1476-4598-7-41 (Pubitemid 351816762)
38. LE Abrey DN Louis N Paleologos, et al. 2007 Survey of treatment recommendations for anaplastic oligodendroglioma Neuro-Oncology 9 314 318 17435180 10.1215/15228517-2007-002 1:CAS:528:DC%2BD2sXpt1agtr8%3D (Pubitemid 47169664)
39. K Ichimura AP Vogazianou L Liu, et al. 2007 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas Oncogene 27 2097 2108 17934521 10.1038/sj.onc.1210848 (Pubitemid 351442746)
40. AP Vogazianou R Chan LM Backlund, et al. 2010 Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses Neuro-Oncology 12 664 678 10.1093/neuonc/nop075
41. C Ramirez C Bowman CA Maurage, et al. 2010 Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors-towards individualized tumor treatment? Neuro-Oncology 12 490 499 20156805 1:CAS:528:DC%2BC3cXotVWmtr0%3D
42. M Jansen S Yip DN Louis 2010 Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers Lancet Neurol 9 717 726 20610347 10.1016/S1474-4422(10)70105-8 1:CAS:528:DC%2BC3cXpsFajurw%3D
43. H Fujisawa M Kurrer RM Reis, et al. 1999 Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter Am J Pathol 155 387 394 10433932 10.1016/S0002-9440(10)65135-8 1:CAS:528:DyaK1MXls1Whs7g%3D (Pubitemid 29370389)
44. J Li C Yen D Liaw, et al. 1997 PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1943 1947 9072974 10.1126/science.275.5308.1943 1:CAS:528:DyaK2sXit1Wgtbk%3D (Pubitemid 27148818)
45. PA Steck MA Pershouse SA Jasser, et al. 1997 Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Nat Genet 15 356 362 9090379 10.1038/ng0497-356 1:CAS:528:DyaK2sXitF2hs70%3D (Pubitemid 27147102)
46. DM Li H Sun 1997 TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta Cancer Res 57 2124 2129 9187108 1:CAS:528:DyaK2sXjslGisrs%3D (Pubitemid 27247025)
47. H Fujisawa RM Reis M Nakamura, et al. 2000 Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas Lab Invest 80 65 72 10653004 10.1038/labinvest.3780009 1:CAS:528:DC%2BD3cXhtVeqs7w%3D (Pubitemid 30067381)
48. M Nakamura Y Yonekawa P Kleihues, et al. 2001 Promoter hypermethylation of the RB1 gene in glioblastomas Lab Invest 81 77 82 11204276 1:CAS:528:DC%2BD3MXht1Sht7w%3D (Pubitemid 32108641)
49. M Nakamura E Ishida K Shimada, et al. 2005 Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas Lab Invest 85 165 175 15592495 10.1038/labinvest.3700223 1:CAS:528: DC%2BD2MXhtFWgtLo%3D (Pubitemid 40208920)
50. H Yan DW Parsons G Jin, et al. 2009 IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765 773 19228619 10.1056/NEJMoa0808710 1:CAS:528: DC%2BD1MXitFWru7o%3D
51. CL Nutt DR Mani RA Betensky, et al. 2003 Gene expression-based classification of malignant gliomas correlates better with survival than histological classification Cancer Res 63 1602 1607 12670911 1:CAS:528:DC%2BD3sXisFaitbc%3D (Pubitemid 36373650)
52. WA Freije FE Castro-Vargas Z Fang, et al. 2004 Gene expression profiling of gliomas strongly predicts survival Cancer Res 64 6503 6510 15374961 10.1158/0008-5472.CAN-04-0452 1:CAS:528:DC%2BD2cXnsFOltbg%3D (Pubitemid 39297907)
53. LA Cooper DA Gutman Q Long, et al. 2010 The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas PLoS One 5 e12548 20838435 10.1371/journal.pone.0012548
54. HS Phillips S Kharbanda R Chen, et al. 2006 Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 157 173 16530701 10.1016/j.ccr.2006.02.019 1:CAS:528:DC%2BD28XivFWjtL4%3D (Pubitemid 43357943)
55. A Li J Walling S Ahn, et al. 2009 Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes Cancer Res 69 2091 2099 19244127 10.1158/0008-5472.CAN-08-2100 1:CAS:528:DC%2BD1MXisFSrurk%3D
56. RGW Verhaak KA Hoadley E Purdom, et al. 2010 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 98 110 20129251 10.1016/j.ccr.2009.12.020 1:CAS:528:DC%2BC3cXkvFKgsL4%3D
57. H Noushmehr DJ Weisenberger K Diefes, et al. 2010 Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 510 522 20399149 10.1016/j.ccr.2010.03.017 1:CAS:528: DC%2BC3cXmslKqsr0%3D
58. JA Chan AM Krichevsky KS Kosik 2005 MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells Cancer Res 65 6029 6033 16024602 10.1158/0008-5472.CAN-05-0137 1:CAS:528:DC%2BD2MXmt1eht7c%3D (Pubitemid 40994386)
59. Y Guan M Mizoguchi K Yoshimoto, et al. 2010 MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance Clin Cancer Res 16 4289 4297 20601442 10.1158/1078-0432.CCR-10-0207 1:CAS:528:DC%2BC3cXhtVajs7jM
60. H Kim W Huang X Jiang, et al. 2010 Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship Proc Natl Acad Sci USA 107 2183 2188 20080666 10.1073/pnas.0909896107 1:CAS:528: DC%2BC3cXhvFCiurw%3D